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Abstract We report five cases of community- and hospi-
tal-acquired infections with oseltamivir- and peramivir-
resistant A(H1N1)pdm09 viruses possessing the neu-
raminidase (NA) H275Y mutation during January–Febru-
ary 2016 in Japan. One case was hospitalized and was
receiving oseltamivir for prophylaxis. The remaining four
cases were not taking antiviral drugs at the time of sam-
pling. These cases were geographically distant and epi-
demiologically unrelated. The five viruses showed *300-
fold rise in IC50 values against oseltamivir and peramivir,
defined as highly reduced inhibition according to the WHO
definition. Overall, the prevalence of the H275Y
A(H1N1)pdm09 viruses was 1.8 % (5/282). The resistant
viruses possessed the V241I, N369 K, and N386 K sub-
stitutions in the NA that have been previously reported
among A(H1N1)pdm09 to alter transmission fitness.
Analysis of Michaelis constant (Km) revealed that two of
the isolates had reduced NA affinity to MUNANA, while
the other three isolates displayed a slightly decreased
affinity compared to the sensitive viruses. Further studies
are needed to monitor the community spread of resistant
viruses and to assess their transmissibility.
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Text
Neuraminidase inhibitors (NAIs), sialic acid analogues, are
the drugs of choice for prevention and treatment of influ-
enza [1]. NAIs block the viral neuraminidase (NA), an
enzyme on the surface of the virus that is important for the
release of newly formed virions from the host cells [2, 3].
Four NAIs (oseltamivir, zanamivir, laninamivir, and per-
amivir) are approved for influenza treatment in Japan [4].
Except for peramivir, NAIs are also licensed for prophy-
laxis against influenza [4]. Resistance to NAIs can be
caused by a single mutation in the NA [2, 3]. The most
frequent resistant-conferring mutation among the influenza
A(H1N1)pdm09 is the H275Y. Viruses carrying this
mutation possess cross resistance to oseltamivir and per-
amivir but remain susceptible to zanamivir and laninamivir
[2, 3]. Community-acquired oseltamivir- and peramivir-
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resistant viruses with the H275Y mutation have been
recently identified in several countries [5–7]. Community
spread of resistant viruses raises concerns regarding their
potential to replace sensitive strains as in the case of the
resistant seasonal A(H1N1) viruses that spread globally
between 2007 and 2008 [2, 3].
We report five cases of community- and hospital-acquired
oseltamivir- and peramivir-resistant A(H1N1)pdm09 viru-
ses during the 2015–2016 season in Japan.
In total, 664 nasopharyngeal swabs were collected from
patients with influenza- like illness (ILI) who visited seven
collaborative clinics or hospitals in Hokkaido, Niigata,
Gunma, Kyoto Nagasaki and Okinawa, Japan between
January 4 and February 29, 2016. Specimens were col-
lected after rapid influenza antigen detection test (RDT)
was positive for influenza A or B. Informed consent was
obtained from the patients or their guardians along with
demographic and clinical data. The Niigata University
Ethics Committee has approved the study. Samples were
sent from the medical facilities to Niigata University for
further virological analysis. Clinical specimens were
inoculated onto Madin-Darby canine kidney cells [8].
Samples with a positive cytopathic effect were typed and
subtyped by using a cycling probe real-time PCR method
which can identify influenza A(H1N1)pdm09, A(H3N2),
B/Victoria, and B/Yamagata [8]. The assay can simulta-
neously detect the presence of the H275Y mutation in
A(H1N1)pdm09 viruses [9]. A total of 282 influenza
A(H1N1)pdm09, 1 A(H3N2), 25 B/Victoria, and 26
B/Yamagata lineage viruses were identified during the
study period. Five of A(H1N1)pdm09 isolates (5/282,
1.8 %) were found to possess the H275Y mutation. This
incidence is similar to the rate (1.0 %) reported by National
Institute of Infectious Disease, Tokyo, Japan during
2015–2016 season (as of 4 March, 2016) [10]. However,
this incidence was lower than that reported during the
2013–2014 season (4.1 %) [7].
One case of infection with H275Y mutant virus was
detected in a hospitalized patient, while the other four were
from patients presenting at community clinics.
Case 1. A 75-year-old woman was admitted to a hospital
in Niigata City with relapse of multiple myeloma on Jan-
uary 13, 2016 (Table 1). Prior to infection, her roommate
was diagnosed as influenza A by a RDT. The roommate
started treatment with oseltamivir on January 21 and was
discharged from the hospital on January 22. As a result,
case 1 was administered a prophylactic dose of oseltamivir
at 75 mg/day as of January 21. The patient developed
cough on January 22, and fever (38 C) on January 25. On
the day of fever onset, an RDT was positive for influenza A
and her treatment was changed to 100 mg peramivir. A
reduced dose (adult dose is normally 300 mg) was given to
the patient because she had a mildly impaired renal
function as a complication to multiple myeloma (BUN
28 mg/dl, Creatinine 1.02 mg/dl). She received one dose of
peramivir each on January 25 and 26 and her fever dropped
to below 37.5 C in the evening of the 26th. The influenza
sample obtained on January 25 was found to possess the
H275Y mutation by real-time PCR.
Cases 2 to 5 visited outpatient clinics in Niigata or
Nagasaki during January–February, 2016, because they had
ILI (Table 1). The patients were prescribed either oselta-
mivir or peramivir according to the Japanese guidelines for
treatment of influenza [4]. A nasopharyngeal swab was
obtained from each patient prior to starting the treatment
and within 48 h from their fever onset. Their fever went
below 37.5 C within 1–3 days after initiating treatment.
The four cases were not epidemiologically linked. Case 3
had a history of train travel to neighboring area 2 days
before the onset of symptoms.
A fluorescent-based enzyme inhibition assay using 20-
(4-methylumbelliferyl)-a-D-N-acetylneuraminic acid
(MUNANA; Sigma-Aldrich Co. LLC, MO, USA) was
performed to assess the susceptibility of the five H275Y
A(H1N1)pdm09 viruses to four NAIs [11]. According to
the World Health Organization, susceptibility of a type A
virus is defined highly reduced to a specific NAIs when its
IC50 increases by more than 100-fold compared to that of
the reference susceptible virus [1, 12]. The H275Y mutant
viruses showed highly reduced susceptibility indicated by a
300-fold increase in the IC50 values for oseltamivir and
peramivir compared to the susceptible reference virus and
thus assessed as resistant (Table 1). These isolates were
susceptible to zanamivir and laninamivir (Table 1).
We next determined the hemagglutinin (HA) and NA
gene sequences of the five H275Y isolates in addition to
eight wild-type (H275) strains. Sanger sequencing of the
HA and NA gene and phylogenetic tree analysis were
performed as previously described [8]. The nucleotide
sequences of HA and NA sequenced in this study are
available through the Global Initiative on Sharing Avian
Influenza Data (GISAID) under the accession numbers:
EPI702620, EPI702622, EPI704037-EPI704042, EPI7040
44-EPI704049, EPI712173, EPI712174, EPI712177-EPI7
12184, EPI712577-EPI712580, EPI781479- EPI781486.
The five H275Y isolates belonged to clade 6B.1 in both the
HA and NA phylogenies forming two geographically
segregated subclusters along with oseltamivir-susceptible
isolates from the same season. The Niigata subcluster was
defined by a D269 N amino acid substitution in the HA
protein and the Nagasaki subcluster had a D35G mutation.
Viruses from Niigata, but not from Nagasaki, uniquely
possessed a V453A substitution in the NA protein. This
suggests that the Niigata and Nagasaki H275Y viruses have
evolved independently rather than being sourced from a
single outbreak of resistant viruses (Fig. 1, Supplementary
90 Virus Genes (2017) 53:89–94
123
Table). The resistant viruses in this study commonly pos-
sessed the V241I, N369 K, and N386 K substitutions in the
NA that have been previously reported among
A(H1N1)pdm09 [5, 7]. Two of the substitutions, V241I and
N369 K, were reported to confer robust viral fitness on the
H275Y mutant viruses [5, 7, 13, 14]. These mutations are
common to clades 5, 6A, 6B, and 7 strains (both suscep-
tible and resistant) and have been reported since
2010–2011 season [5, 7, 13]. Takashita et al. have recently
suggested using structural modeling that the N386 K sub-
stitution which was detected in this study slightly impairs
the stabilizing effect of the V241I and N369 K mutations
[7]. A survey of the influenza sequences in the public
database (Influenza Sequence Database, http://www.ncbi.
nlm.nih.gov/genomes/FLU/FLU.html) revealed that the
N386 K mutation is not unique to H275Y viruses. We
found that this mutation has been also reported among
recent A(H1N1)pdm09 viruses (including H275 and
H275Y strains) at increasing frequencies: 5.7 % (42/734)
in 2013, 61.2 % (281/459) in 2014, 100 % (350/350) in
2015 (as of Aug 12, 2016). The effect of these mutations on
the fitness of resistant viruses remains to be explored.
To assess the enzymatic properties of the resistant
viruses, NA kinetic parameters (Km and Vmax) were
measured for the five resistant and five sensitive isolates
with genetically similar background (A/Niigata/15F185/
2016, A/Kyoto/15K029/2016, A/Nagasaki-Isahaya/15I007/
2016, A/Nagasaki/15N011/2016, A/Nagasaki/15N026/
2016) (Fig. 1.). In addition, the WHO sensitive and resis-
tant virus control, A/Perth/265/2009 and A/Perth/261/2009,
Table 1 Demographic characteristics and viral investigation of five patients infected with H275Y mutant viruses in 2016
Cases Case 1 Case 2 Case 3 Case 4 Case 5
Patient
information
Age (years) 75 41 37 1 2
Sex Female Male Female Female Female
Area in Japan Niigata Nagasaki Nagasaki Niigata Niigata
Date of fever onset 25-Jan 9-Jan 10-Jan 5-Feb 12-Feb
Date of therapy start 25-Jan 11-Jan 11-Jan 6-Feb 12-Feb
NAIs used Peramivir Oseltamivir Peramivir Oseltamivir Oseltamivir
Fever duration(days) 1 1 3 3 2
Travel history No No Yesa No No
History of NAI treatment Yesb
Oseltamivir
No No No No
Underlying condition Yesc No No No No
Hospitalization Yesc No No No No
Viral
investigations
















Oseltamivir 353.38 ± 13.32 321.59 ± 19.81 352.59 ± 23.03 320.38 ± 50.33 346.31 ± 44.37
Peramivir 19.67 ± 2.82 23.88 ± 1.72 22.30 ± 0.83 20.10 ± 1.68 18.77 ± 0.70
Zanamivir 0.74 ± 0.03 0.74 ± 0.04 0.69 ± 0.07 0.79 ± 0.042 0.69 ± 0.08




Km [lM] 33.42 ± 5.15 73.22 ± 27.65 61.79 ± 12.10 29.48 ± 4.78 27.04 ± 3.02
Vmax[lM/
min]
0.33 ± 0.02 0.56 ± 0.31 0.40 ± 0.03 0.45 ± 0.06 0.31 ± 0.02
a Case 3 was in Fukuoka prefecture, Japan two days before the onset of fever
b A roommate had influenza A onset on Jan 21 and Case 1 started prophylaxis by oseltamivir
c Case 1 had been hospitalized for treatment for multiple myeloma
d Data are mean ? SD of 3 independent determinations. IC50 values for reference sensitive virus (A/PERTH/265/2009) against four neu-
raminidase inhibitors (oseltamivir, peramivir, zanamivir, and laninamivir) were 1.33 ± 0.07, 0.08 ± 0.01, 0.59 ± 0.10, 0.27 ± 0.02, nM, and
those for the resistant reference virus with H275Y mutation (A/PERTH/261/2009) were 276.00 ± 39.61, 30.16 ± 2.14, 0.62 ± 0.06,
0.38 ± 0.03 nM, respectively
e Data are mean ± SD of 3–5 independent determinations. Average values for Km [lM] and Vmax [lM/min] of 5 sensitive viruses possessing
similar genetic sequences during the same seasons were 23.28 ± 2.04, and 0.36 ± 0.04. Those for the reference WHO sensitive virus (A/
PERTH/265/2009) were 18.28 1.67, and 0.22 ± 0.01, and for the WHO resistant virus with H275Y mutation (A/PERTH/261/2009) were
69.38 ± 29.68, and 0.38 ± 0.05, respectively
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were included in the analysis. The enzymatic kinetics was
measured by a fluorescence-based assay using MUNANA
and measurement of subsequent release of the fluorescent
product 4-methylumbelliferone (4-MU) by NA activity,
using the method reported by Marathe et al. [15]. The Km
and Vmax were determined by fitting the data to Michaelis–
Menten equation [15, 16] using Microsoft Excel software
(Microsoft Corporation, WA, USA). Two of the viruses (A/
Nagasaki/15N002/2016 and A/Nagasaki/15N005/2016)
demonstrated a *threefold increase inKmvalues compared
to sensitive viruses, which also similar to the WHO resistant
control. The remaining resistant viruses (A/Niigata/
15NU001/2016, A/Niigata/15F255/2016, A/Niigata/
15F341/2016) had only 1.1- to 1.5-fold increase in their Km
compared to the sensitive viruses. These results suggested
that the H275Y viruses possess lower affinity to the substrate
which may attenuate their transmission fitness [16] as in the
case of the resistant viruses reported with low frequency in
the community in 2009 [2, 3]. However, the rest of viruses
displayed equal or slightly higher Km values and are thus
expected to have a comparable fitness to sensitive viruses,
which might pose concerns about their potential to spread in
the community.
Of note, one patient had received prophylactic treatment
by oseltamivir because she shared the same room at the
hospital with an influenza-infected patient who was also
being administered oseltamivir. However, we could not
obtain a sample from the roommate to confirm whether the
H275Y mutation had emerged in the patient or was trans-
mitted from the roommate (hospital-acquired). On the other
hand, the remaining four patients did not have a history of



























































































































































































Fig. 1 Phylogenetic analysis of the hemagglutinin (a) and neu-
raminidase gene (b) of the five H275Y mutant influenza
A(H1N1)pdm09 strains isolated in Niigata and Nagasaki, Japan in
January to February 2016. Multiple alignment was constructed by the
neighbor-joining method with MEGA, version6. Bootstrap value
determined for 1000 interactions. Only values of greater than 70 %
are shown. The H275Y mutant strains are shown in red, and those
detected in the 2015/2016 season are indicated in closed circle. The
sensitive strains that were used for enzymatic property measurement
(Km and Vmax) are colored blue. Reference sequences of
A(H1N1)pdm09 strains downloaded from the GenBank and GISAID
EpiFlu Database (www.gisaid.org.). The amino acid substitutions
relative to the A/California/07/2009 strain are shown in the phylo-
genetic tree (Color figure online)
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Thus, it is likely that these strains were transmitted in the
community.
In our study, three of the patients were treated with
oseltamivir and two with peramivir. All patients started the
treatment within 48 h of fever onset and fully recovered
without complications. The duration of fever among the
five cases was 1–3 days, in range with the data reported on
patients infected with the H275Y mutant virus during the
2013–2014 season in Hokkaido, Japan [17]. Kakuya et al.
demonstrated in a small number of pediatric patients that
oseltamivir and peramivir retain the clinical effectiveness
against the H275Y mutant virus [17]. In contrast, we have
previously shown that children less than 6 years of age
infected with the seasonal H275Y A(H1N1) virus had
delayed fever resolution compared with those infected with
the sensitive virus [18]. Another Japanese group demon-
strated that oseltamivir was less effective for children but it
was effective for adult infected with seasonal H275Y
A(H1N1) virus [19]. This discrepancy in findings could be
due to differences in sample size, and between seasonal
A(H1N1) or A(H1N1)pdm09 infections. Further studies are
warranted to better assess clinical effectiveness of oselta-
mivir and peramivir against the H275Y A(H1N1)pdm09
variant.
The identification of community- and potentially hos-
pital-acquired cases of oseltamivir- and peramivir-resistant
isolates is a reason for concern and highlights the impor-
tance of continued monitoring of the susceptibilities of
influenza viruses to NAIs.
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